HUP0103234A2 - Alkil-hidrogén-fumarátok alkalmazása pikkelysömör, pszoriatikus izületi gyulladás és Crohn-féle regionális bélhurut kezelésére - Google Patents

Alkil-hidrogén-fumarátok alkalmazása pikkelysömör, pszoriatikus izületi gyulladás és Crohn-féle regionális bélhurut kezelésére

Info

Publication number
HUP0103234A2
HUP0103234A2 HU0103234A HUP0103234A HUP0103234A2 HU P0103234 A2 HUP0103234 A2 HU P0103234A2 HU 0103234 A HU0103234 A HU 0103234A HU P0103234 A HUP0103234 A HU P0103234A HU P0103234 A2 HUP0103234 A2 HU P0103234A2
Authority
HU
Hungary
Prior art keywords
neurodermatitis
psoriatic arthritis
fumerates
utilization
regional enteritis
Prior art date
Application number
HU0103234A
Other languages
English (en)
Inventor
Rajendra K. Joshi
Hans-Peter Strebel
Original Assignee
Fumapharm Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fumapharm Ag. filed Critical Fumapharm Ag.
Publication of HUP0103234A2 publication Critical patent/HUP0103234A2/hu
Publication of HUP0103234A3 publication Critical patent/HUP0103234A3/hu
Publication of HU228848B1 publication Critical patent/HU228848B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A találmány tárgya egy vagy több, (I) általános képletű, ahol Rjelentése 1-5 szénatomos alkilcsoport, alkil-hidrogén-fumarátnak,adott esetben (II) általános képletű dialkil-fumaráttal képzettkeverékének és adott esetben a szokásos, gyógyászati szempontbólalkalmazható közeganyagnak vagy vivőanyagnak felhasználása az övsömör(psoriasis), a pszoriatikus ízületi gyulladás (arthritis), a neuro-dermatitis (neurodermatitis) és a Crohn-féle regionális bélhurut(enteritis) kezelésére szolgáló, mikrotabletta vagy mikropelletalakjában lévő gyógyszerkészítmény előállításához. Ó
HU0103234A 1998-03-31 1998-12-08 Utilization of alkyl hydrogen fumerates for treating psoriasis, psoriatic arthritis, neurodermatitis and regional enteritis HU228848B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19814358A DE19814358C2 (de) 1998-03-31 1998-03-31 Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
PCT/EP1998/007956 WO1999049858A1 (de) 1998-03-31 1998-12-08 Verwendung von alkylhydrogenfumaraten zur behandlung von psoriasis, psoriatischer arthritis, neurodermitis und enteritis regionalis crohn

Publications (3)

Publication Number Publication Date
HUP0103234A2 true HUP0103234A2 (hu) 2002-01-28
HUP0103234A3 HUP0103234A3 (en) 2003-11-28
HU228848B1 HU228848B1 (en) 2013-06-28

Family

ID=7863089

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103234A HU228848B1 (en) 1998-03-31 1998-12-08 Utilization of alkyl hydrogen fumerates for treating psoriasis, psoriatic arthritis, neurodermatitis and regional enteritis

Country Status (26)

Country Link
US (1) US6277882B1 (hu)
EP (1) EP1059920B1 (hu)
JP (1) JP3527890B2 (hu)
CN (1) CN1150898C (hu)
AT (1) ATE219936T1 (hu)
AU (1) AU745281B2 (hu)
BG (1) BG64744B1 (hu)
BR (1) BRPI9815772B8 (hu)
CA (1) CA2283915C (hu)
CZ (1) CZ291788B6 (hu)
DE (2) DE19814358C2 (hu)
DK (1) DK1059920T3 (hu)
EE (1) EE04702B1 (hu)
ES (1) ES2179551T3 (hu)
HK (1) HK1035134A1 (hu)
HU (1) HU228848B1 (hu)
IL (1) IL136835A (hu)
NO (1) NO327750B1 (hu)
NZ (1) NZ505341A (hu)
PL (1) PL191803B1 (hu)
PT (1) PT1059920E (hu)
RS (1) RS49658B (hu)
RU (1) RU2197233C2 (hu)
SK (1) SK285187B6 (hu)
TR (1) TR200001829T2 (hu)
WO (1) WO1999049858A1 (hu)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
JP2004523511A (ja) * 2001-01-12 2004-08-05 フーマファーム アーゲー フマル酸アミド類
DE10217314A1 (de) 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
DE10360869A1 (de) * 2003-09-09 2005-04-07 Fumapharm Ag Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
AU2004269903B2 (en) * 2003-09-09 2010-09-02 Biogen International Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
PT2801354T (pt) 2004-10-08 2017-06-05 Forward Pharma As Composições farmacêuticas de libertação controlada compreendendo um éster de ácido fumárico
US20080004344A1 (en) * 2004-11-10 2008-01-03 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
EP1915334A2 (en) * 2005-07-07 2008-04-30 Aditech Pharma AB Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
EP2186819A1 (en) 2005-07-07 2010-05-19 Aditech Pharma AG Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
JP2009510137A (ja) * 2005-10-07 2009-03-12 アディテック・ファルマ・アクチボラゲット フマル酸エステルを含む制御放出医薬組成物
EP2680007A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2 screening assays and related methods and compositions
WO2008096271A2 (en) * 2007-02-08 2008-08-14 Ralf Gold Neuroprotection in demyelinating diseases
RU2554347C2 (ru) 2008-08-19 2015-06-27 Ксенопорт, Инк. Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения
UA112975C2 (uk) 2009-01-09 2016-11-25 Форвард Фарма А/С Фармацевтичний склад, що містить в матриці, яка піддається ерозії, один або більше ефірів фумарової кислоти
CN103649041A (zh) 2011-06-08 2014-03-19 比奥根艾迪克Ma公司 制备高纯度和结晶的富马酸二甲酯的方法
RU2014125430A (ru) 2011-11-24 2015-12-27 Синтон Бв Контролируемое высвобождение частиц, содержащих диметилфумарат
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US20130216615A1 (en) * 2012-02-07 2013-08-22 David Goldman Pharmaceutical Compositions Containing Dimethyl Fumarate
WO2013119791A1 (en) 2012-02-07 2013-08-15 Xenoport, Inc. Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
KR101449114B1 (ko) * 2012-08-21 2014-10-13 바이오스펙트럼 주식회사 푸마르산을 유효성분으로 포함하는 항염 조성물
WO2014031844A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US9597292B2 (en) 2012-08-22 2017-03-21 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
US20140171504A1 (en) 2012-12-14 2014-06-19 Georgia Regents Research Institute, Inc. Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
EP2934503B1 (en) 2012-12-21 2019-04-10 Biogen MA Inc. Deuterium substituted fumarate derivatives
SG10201707543PA (en) 2013-03-14 2017-11-29 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
KR20210139485A (ko) 2013-08-26 2021-11-22 에프더블유피 아이피 에이피에스 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물
WO2015035184A1 (en) 2013-09-06 2015-03-12 Xenoport, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
WO2015042294A1 (en) 2013-09-18 2015-03-26 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
MX2017003215A (es) * 2014-09-12 2018-01-24 Tobira Therapeutics Inc Terapia de combinacion con cenicriviroc para el tratamiento de la fibrosis.
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
ES2879611T3 (es) 2015-02-08 2021-11-22 Alkermes Pharma Ireland Ltd Composiciones de profármaco de monometilfumarato
DK3273951T3 (da) 2015-03-27 2020-11-02 Symbionyx Pharmaceuticals Inc Sammensætninger og fremgangsmåder til behandling af psoriasis
WO2017060420A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected fumaric acid-based metabolites for the treatment of autoimmune diseases
CN105496804A (zh) * 2015-12-25 2016-04-20 知识产权全资有限公司 用于处理头发以及治疗头部牛皮藓的配方及其试剂盒和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) * 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
DE3127432A1 (de) * 1981-07-11 1983-02-03 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von fumarsaeuremonoester
US5242905A (en) * 1987-09-04 1993-09-07 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
US5214196A (en) * 1987-09-04 1993-05-25 Dexter Chemical Corporation Diethyl ester of di-glycyl fumaramide
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US5424332A (en) * 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
DE8714143U1 (de) * 1987-10-23 1988-03-24 Werler Kunststoffwerke GmbH & Co, 4760 Werl Sitz- und/oder Liegemöbel
DE3834794A1 (de) 1988-10-12 1990-04-19 F Schielein Oral zu verabreichendes mittel zur behandlung von psoriasis
AU1271592A (en) * 1991-01-18 1992-08-27 Dexter Chemical Corporation Malic acid derivatives and compositions for the treatment of psoriasis
US5407772A (en) * 1993-11-30 1995-04-18 Xerox Corporation Unsaturated polyesters
US5972363A (en) * 1997-04-11 1999-10-26 Rohm And Haas Company Use of an encapsulated bioactive composition

Also Published As

Publication number Publication date
TR200001829T2 (tr) 2000-11-21
YU32000A (sh) 2002-03-18
HUP0103234A3 (en) 2003-11-28
IL136835A (en) 2005-05-17
DE59804704D1 (de) 2002-08-08
EP1059920B1 (de) 2002-07-03
DE19814358A1 (de) 1999-10-07
CN1150898C (zh) 2004-05-26
NO327750B1 (no) 2009-09-14
NZ505341A (en) 2002-04-26
HK1035134A1 (en) 2001-11-16
PT1059920E (pt) 2002-11-29
EE200000440A (et) 2001-12-17
ATE219936T1 (de) 2002-07-15
DE19814358C2 (de) 2002-01-17
NO20002872L (no) 2000-06-06
BRPI9815772A (pt) 2000-11-21
CZ20003086A3 (cs) 2000-11-15
PL191803B1 (pl) 2006-07-31
CA2283915C (en) 2002-12-03
BRPI9815772B8 (pt) 2021-07-06
ES2179551T3 (es) 2003-01-16
SK285187B6 (sk) 2006-08-03
EE04702B1 (et) 2006-10-16
RU2197233C2 (ru) 2003-01-27
DK1059920T3 (da) 2002-10-14
AU2159399A (en) 1999-10-18
HU228848B1 (en) 2013-06-28
US6277882B1 (en) 2001-08-21
JP2002509883A (ja) 2002-04-02
BRPI9815772B1 (pt) 2016-02-10
RS49658B (sr) 2007-09-21
CN1284870A (zh) 2001-02-21
WO1999049858A1 (de) 1999-10-07
IL136835A0 (en) 2001-06-14
EP1059920A1 (de) 2000-12-20
JP3527890B2 (ja) 2004-05-17
AU745281B2 (en) 2002-03-21
BG64744B1 (bg) 2006-02-28
CZ291788B6 (cs) 2003-05-14
CA2283915A1 (en) 1999-09-30
NO20002872D0 (no) 2000-06-06
PL341240A1 (en) 2001-03-26
BG104566A (en) 2001-01-31
SK7922000A3 (en) 2001-01-18

Similar Documents

Publication Publication Date Title
HUP0103234A2 (hu) Alkil-hidrogén-fumarátok alkalmazása pikkelysömör, pszoriatikus izületi gyulladás és Crohn-féle regionális bélhurut kezelésére
MX9701292A (es) Compuestos espiro-azabiciclicos utiles en la terapia.
PL323825A1 (en) Peptidyloheterocycli compounds useful in treating diorders associated with thrombosin
MY108885A (en) Heterocyclic-cyclic amine derivatives.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE69430440T2 (de) Zusammensetzungen zur inhibition von retroviraler verbreitung, die 2',3'-dideoxy-inosin und hydroxyharnstoff enthalten
AU2490297A (en) Use of strontium salts for the production of pharmaceutical compositions intended for the treatment of arthrosis
GB9418912D0 (en) Pharmaceutically active compounds
IL104788A0 (en) Process for the purification of perfluorocarbons
HUP0100066A2 (hu) Egy diol és egy alfa-hidroxisav keverékének alkalmazása hiperkeratózisos bőrbetegségek kezelésére
IL95875A0 (en) Illudin analogs,pharmaceutical compositions containing the same and methods for the use thereof
ATE223721T1 (de) Edelfosin zur behandlung von hirntumoren
HUP0102447A2 (hu) Új oktahidro-6,10-dioxo-6H-piridazino[1,2-a][1,2]diazepin-1-karbonsav-származékok, eljárás a vegyületek előállítására és alkalmazásuk gyógyászati hatóanyagok előállítására
DK7286A (da) Octahydroindoliziner
BR9800928A (pt) Material cosmético, e, processo para preparar o mesmo.
PT740657E (pt) 4-aril-isoindois com actividade analgesica
DE69512522T2 (de) Antimessenger oligonukleotide und urokinaserezeptor umkehrung des invasive phänotyps transformieter menschlicher fibroblasten durch antimessenger oligonukleotidinhibierung von urokinaserezeptoren-expression
ES8707204A1 (es) Procedimiento para preparar diazepinoindoles
ES2000678A6 (es) Procedimiento para la obtencion de embonatos de los acidos quinolon-carboxilicos y sus derivados
GB9425071D0 (en) Chondrocyte cell lines
UA28854A (uk) Спосіб лікування гострого панкреатиту
MX9207565A (es) Hidroxilacion.
MX9705136A (es) Fusacandinas antifungales.
JO1590B1 (en) Use of calcium sulfate to improve fermentation of organic waste

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees